Clostridium difficile Strains Associated with Nosocomial Infections - Laboratory Diagnosis, Prevalence, Susceptibility and Molecular Characterization of the Isolates

Main Article Content

Kiril Mihajlov
Elena Trajkovska-Dokić

Abstract

Although there was not much attention about the role of this bacterium in the past, Clostridium difficile is one of the most important agents associated with nosocomial infections today. The main reason for this is its resistance against many antibiotics and environmental conditions as a result to its ability to form spores and to produce toxins.

There are no data for the prevalence of the infections with Clostridium difficile in the Republic of Macedonia. Also, the resistance and the molecular characterization of the isolated strains haven't been explored.

Using the "Pubmed Central" database, we have analyzed 65 peer reviewed articles concerning this topic and we have collected interesting information about Clostridium difficile strains that had been isolated from hospitalized patients from all over the world, suffering mostly from antibiotic associated diarrhea.

In terms of diagnosis, the tree-step algorithm has been recommended (direct screening of glutamate dehydrogenase- GDH, plus fecal detection of toxins A and B and toxigenic culture) as an effective way for the detection of this infection. That way, we would be able to detect many cases that would have been missed if using the other algorithms. As a result of this, direct transmission of C.difficile in the hospitals can be prevented and costs of prolonged hospitalization can be reduced.

Oral metronidazole or vancomycin is the standard therapy for C. difficile infection.

Patients with severe and refractory C. difficile infections have been treated successfully with intravenous tigecycline. Tigecycline had the lowest MIC90 values for C. difficile and was followed by daptomycin, metronidazole, and vancomycin (1 μg/ml). Clindamycin showed the highest MICs of all antimicrobial agents tested. The use of clindamycin is associated with a high risk of inducing C. difficile infection.

In most of the studies, all of the strains have been susceptible to metronidazole, vancomycin, daptomycin and tigecycline whereas only strains belonging to ribotype 018 have been resistant to moxifloxacin. Ribotype 018 is the most frequent ribotype and all the isolates of this ribotype proved resistant to fluoroqinolones, suggesting that the increased use of this antibiotics has played a determinant role in selection and spread of this strains.

Outbreaks of C. difficile infections, particularly toxigenic strains such as ribotype NAP1/027, were often reported in the Europe, United States and Canada.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Mihajlov K, Trajkovska-Dokić E. Clostridium difficile Strains Associated with Nosocomial Infections - Laboratory Diagnosis, Prevalence, Susceptibility and Molecular Characterization of the Isolates. Maced Med Electron J [Internet]. 2015 Jul. 15 [cited 2024 Jul. 16];1(1):1-8. Available from: https://id-press.eu/mmej/article/view/350
Section
Basic Medicine

References

Hall I, O'Toole E. Intestinal flora in newborn infants. Am J Dis Child. 1935;49:390. DOI: https://doi.org/10.1001/archpedi.1935.01970020105010

Bartlett JG, Chang TW, Moon N, Onderdonk AB. Antibiotic-induced lethal enterocolitis in hamsters: studies with eleven agents and evidence to support the pathogenic role of toxin-producing Clostridia. Am J Vet Res. 1978;39:1525–1530.

Oeding P, Austarheim K. The occurrence of staphylococci in the intestinal content after treatment with antibiotics; a bacteriological and anatomical study of routine autopsy material. Acta Pathol Microbiol Scand. 1954;35:473–483 DOI: https://doi.org/10.1111/j.1699-0463.1954.tb00895.x

Prohaska JV. Pseudomembranous enterocolitis; the experimental induction of the disease with Staphylococcus aureus and its enterotoxin. AMA Arch Surg. 1959;79:197–206. DOI: https://doi.org/10.1001/archsurg.1959.04320080033005

Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis. 2008;14:929–931. DOI: https://doi.org/10.3201/eid1406.071447

SurawiczCM. Clostridium difficile disease: diagnosis and treatment. Gastroenterologist. 1998; 6:60-5.

Samore MH. Epidemiology of nosocomial Clostridium difficile diarrhoea. Journal of hospital infection. 1999; 43:183-90. DOI: https://doi.org/10.1016/S0195-6701(99)90085-3

Zadik PM, Moore AP. Antimicrobial associations of an outbreak of diarrhoea due to Clostridium difficile. Journal of hospital infection. 1998; 39:189-93. DOI: https://doi.org/10.1016/S0195-6701(98)90257-2

Barbut F, Lalande V, Daprey G, Cohen P, Marle N, Burghoffer B, Petit JC. Usefulness of simultaneous detection of toxin A and glutamate dehydrogenase for the diagnosis of Clostridium difficile-associated diseases. Eur J Clin Microbiol Infect Dis. 2000; 19: 481-484. DOI: https://doi.org/10.1007/s100960000297

Kelly CP, LaMont JT. Clostridium difficile–more difficult than ever. N Engl J Med. 2008; 359:1932–1940.

McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989; 320: 204–210. DOI: https://doi.org/10.1056/NEJM198901263200402

Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis. 1992; 166: 561–567. DOI: https://doi.org/10.1093/infdis/166.3.561

Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 20111; 365:1693–1703 DOI: https://doi.org/10.1056/NEJMoa1012413

Rudensky B, Rosner S, Sonnenblick M, van Dijk Y, Shapira E, et al. The prevalence and nosocomial acquisition of Clostridium difficile in elderly hospitalized patients. Postgrad Med J. 1993; 69: 45–47.

Hutin Y, Casin I, Lesprit P, Welker Y, Decazes JM, et al. Prevalence of and risk factors for Clostridium difficile colonization at admission to an infectious diseases ward. Clin Infect Dis. 1997; 24: 920–924. DOI: https://doi.org/10.1093/clinids/24.5.920

Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000; 342: 390–397. DOI: https://doi.org/10.1056/NEJM200002103420604

Samore MH, DeGirolami PC, Tlucko A, Lichtenberg DA, Melvin ZA, et al. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis. 1994; 18: 181–187. DOI: https://doi.org/10.1093/clinids/18.2.181

Walker KJ, Gilliland SS, Vance-Bryan K, Moody JA, Larsson AJ, et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc. 1993; 41: 940–946. DOI: https://doi.org/10.1111/j.1532-5415.1993.tb06759.x

McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis. 1990; 162: 678–684. DOI: https://doi.org/10.1093/infdis/162.3.678

Arvand M, Moser V, Schwehn C, Bettge-Weller G, Hensgens MP, et al. High prevalence of Clostridium difficile colonization among nursing home residents in Hesse, Germany. PLoS One. 2012; 7: e30183. DOI: https://doi.org/10.1371/journal.pone.0030183

Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis. 2007; 45: 992–998.

Lawrence SJ, Puzniak LA, Shadel BN, Gillespie KN, Kollef MH, et al. Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure. Infect Control Hosp Epidemiol. 2007;28:123–130. DOI: https://doi.org/10.1086/511793

Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet. 1998; 351: 633–636. DOI: https://doi.org/10.1016/S0140-6736(97)08062-8

Alcalí L, Sanchez-Cambronero L, Catalan MP, Sanchez-Somolinos M, Pelaez MT, Marin M, Bouza E. Comparison of three commercial methods for rapid detection of Clostridium difficile toxins A and B from fecal specimens. J Clin Microbiol. 2008;46:3833-3835. DOI: https://doi.org/10.1128/JCM.01060-08

Reller ME, Lema CA, Perl TM, Cai M, Ross TL, Speck KA, Carroll KC. Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J Clin Microbiol. 2007; 45:3601-3605. DOI: https://doi.org/10.1128/JCM.01305-07

Ticehurst JR, Aird DZ, Dam LM, Borek AP, Hargrove JT, Carroll KC. Effective detection of toxigenic Clostridium difficile by a twostep algorithm including tests for antigen and cytotoxin. J Clin Microbiol. 2006;44:1145-1149. DOI: https://doi.org/10.1128/JCM.44.3.1145-1149.2006

Sharp S, Ruden LO, Pohl JC, Hatcher PA, Jayne LM, Ivie WM. Evaluation of the C. Diff Quik Chek Complete assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of Clostridium difficile disease. J Clin Microbiol. 2010; 48:2082-2086. DOI: https://doi.org/10.1128/JCM.00129-10

Gilligan PH. Is a two-step glutamate dehyrogenase antigen-cytotoxicity neutralization assay algorithm superior to the Premier toxin A and B enzyme immunoassay for laboratory detection of Clostridium difficile? J Clin Microbiol. 2008; 46: 1523- 1525. DOI: https://doi.org/10.1128/JCM.02100-07

Tenover FC, Novak-Weekley S, Woods CW, Peterson LR, Davis T, Schreckenberger P, Fang FC, Dascal A, Gerding DN, Nomura JH, Goering RV, Akerlund T, Weissfeld AS, Jo Baron E, Wong E, Marlowe EM, Whitmore J, Persing DH. Impact of strain type on detection of toxigenic clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol. 2010;48(10):3719. DOI: https://doi.org/10.1128/JCM.00427-10

Sloan LM, Duresko BJ, Gustafson DR, Rosenblatt JE. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol. 2008;46:1996-2001. DOI: https://doi.org/10.1128/JCM.00032-08

Thomson JR, Kaul KL. Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. Clin Infect Dis. 2007;45:1152-1160. DOI: https://doi.org/10.1086/522185

Kvach EJ, Ferguson D, Riska PF, Landry ML. Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection. J Clin Microbiol. 2010;48: 109–114. DOI: https://doi.org/10.1128/JCM.01630-09

Knetsch CW, Bakker D, de Boer RF, Sanders I, Hofs S, et al. Comparison of real-time PCR techniques to cytotoxigenic culture methods for diagnosing Clostridium difficile infection. J Clin Microbiol. 2011; 49: 227–231. DOI: https://doi.org/10.1128/JCM.01743-10

Loo VG, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442-2449. DOI: https://doi.org/10.1056/NEJMoa051639

McDonald LC, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-2441. DOI: https://doi.org/10.1056/NEJMoa051590

Warny M, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005; 366:1079-1084. DOI: https://doi.org/10.1016/S0140-6736(05)67420-X

Clements AC, Magalhí£es RJ, Tatem AJ, Paterson DL, Riley TV. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect. Dis. 2010;10:395-404. DOI: https://doi.org/10.1016/S1473-3099(10)70080-3

Kelly CP, LaMont JT. Clostridium difficile"”more difficult than ever. N Engl J Med. 2008;359:1932-1940.

Pépin J, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254-1260. DOI: https://doi.org/10.1086/496986

Rudensky B, Rosner S, Sonnenblick M, van Dijk Y, Shapira E, et al. The prevalence and nosocomial acquisition of Clostridium difficile in elderly hospitalized patients. Postgrad Med J. 1993; 69: 45–47. DOI: https://doi.org/10.1136/pgmj.69.807.45

Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis. 2007; 45: 992–998. DOI: https://doi.org/10.1086/521854

Hornbuckle K, Chak A, Lazarus HM, Cooper GS, Kutteh LA, et al. Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients. Ann Oncol. 1998; 9: 307–311. DOI: https://doi.org/10.1023/A:1008295500932

Kent KC, Rubin MS, Wroblewski L, Hanff PA, Silen W. The impact of Clostridium difficile on a surgical service: a prospective study of 374 patients. Ann Surg. 1998; 227: 296–301. DOI: https://doi.org/10.1097/00000658-199802000-00021

McGowan AP, Lalayiannis LC, Sarma JB, Marshall B, Martin KE, et al. Thirty-day mortality of Clostridium difficile infection in a UK National Health Service Foundation Trust between 2002 and 2008. J Hosp Infect. 2011; 77: 11–15. DOI: https://doi.org/10.1016/j.jhin.2010.09.017

Moro ML, Mongardi M, et al. Prevenzione e controllo delle infezioni da Clostridium difficile. Documento di indirizzo SIMPIOS (Societí Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie). Giornale Italiano delle Infezioni Ospedaliere. 2009;16: 2-40.

Wilcox MH, Eastwood KA. Evaluation report: Clostridium difficile toxin detection assays. Centre for Evidence-based Purchasing publication no. CEP08054. Centre for Evidence-based Purchasing, NHS Purchasing and Supplies Agency, National Health Service, London, United Kingdom, 2009. http://www.pasa.nhs.uk/pasa/Doc.aspx?Path_%5bM N%5d%5bSP%5d/NHSprocurement/CEP/CEP080 54.pdf, (2009).

Delmee M, Broeck JV, Simon A, Le Janssens M, Avesani V. Laboratory diagnosis of Clostridium difficile associated diarrhoea: a plea for culture. J Med Microbiol. 2005;54:187-191. DOI: https://doi.org/10.1099/jmm.0.45844-0

Mulligan ME, Rolfe RD, Finegold SM, George WL. Contamination of a hospital environment by Clostridium difficile. Curr Microbiol. 1979;3:173-175. DOI: https://doi.org/10.1007/BF02601862

Brazier JS, Fawley W, Freeman J, Wilcox MH. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother. 2001;48:741-742. DOI: https://doi.org/10.1093/jac/48.5.741

Kelly CP, Lamont JT. Clostridium difficile. More difficult than ever. N Engl J Med. 2008;359:1932- 1940. DOI: https://doi.org/10.1056/NEJMra0707500

Russello G, Russo A, Sisto F, Scaltrito MM, Farina C. Laboratory diagnosis of Clostridium difficile associated diarrhoea and molecular characterization of clinical isolates. New Microbiol. 2012;35(3):307-16.

Spigaglia P, Barbanti F, Dionisi AM, Mastrantonio P. Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR-ribotype 018. J Clin Microbiol. 2010;48:2892-2896. DOI: https://doi.org/10.1128/JCM.02482-09

Goorhuis A, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis. 2008;47:1162-1170. DOI: https://doi.org/10.1086/592257

Lin YC, Huang YT, Tsai PJ, Lee TF, Lee NY, Liao CH, Lin SY, Ko WC, Hsueh PR. Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan. Antimicrob Agents Chemother. 2011;55(4):1701-5. DOI: https://doi.org/10.1128/AAC.01440-10

Drudy D, et al. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother. 2006;58:1264-1267. DOI: https://doi.org/10.1093/jac/dkl398

King CHR, Lin L, Leunk R. In vitro resistance development to nemonoxacin for Streptococcus pneumoniae, abstr. C1-1971. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC, 2008.

Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut. 1986; 27:1169-1172. DOI: https://doi.org/10.1136/gut.27.10.1169

Owens RC, Jr, Donskey CJ, Gaynes RP, Loo VG, Muto C A. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl. 1):S19-S31. DOI: https://doi.org/10.1086/521859

Norén T, Alriksson I, Akerlund T, Burman LG, Unemo M. In vitro susceptibility to 17 antimicrobials among clinical Clostridium difficile isolates collected 1993-2007 in Sweden. Clin Microbiol Infect. 2010;16:1104-1110. DOI: https://doi.org/10.1111/j.1469-0691.2009.03048.x

Hecht DW, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother. 2007;51:2716-2719. DOI: https://doi.org/10.1128/AAC.01623-06

Pépin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol. 2007;102:2781-2788. DOI: https://doi.org/10.1111/j.1572-0241.2007.01539.x

Herpers BL, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractoryClostridium difficile infection. Clin Infect Dis. 2009;48:1732-1735. DOI: https://doi.org/10.1086/599224

Nord CE, Sillerstrí¶m E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother. 2006;50:3375-3380. DOI: https://doi.org/10.1128/AAC.00373-06

Klaassen CH, van Haren HA, Horrevorts AM. Molecular fingerprinting of Clostridium difficile isolates: pulsed-field gel electrophoresis versus amplified fragment length polymorphism. J Clin Microbiol. 2002;40:101-104. DOI: https://doi.org/10.1128/JCM.40.1.101-104.2002

Pasanen T, Kotila SM, Horsma J, Virolainen A, Jalava J, Ibrahem S, Antikainen J, Mero S, Tarkka E, Vaara M, Tissari P. Comparison of repetitive extragenic palindromic sequence-based PCR with PCR ribotyping and pulsed-field gel electrophoresis in studying the clonality of Clostridium difficile. Clin Microbiol Infect. 2011;17(2):166-75. DOI: https://doi.org/10.1111/j.1469-0691.2010.03221.x